Assessing Effects of Treatment With Lisdexamfetamine Dimesylate for Pediatric ADHD Using a Parental Survey | CNS Spectrums | Cambridge Core (original) (raw)

References

  1. Vyvanse® [package insert]. Wayne, PA: Shire US Inc. 2008.Google Scholar

  2. Biederman, J, Boellner, SW, Childress, A, López, FA, Krishnan, S, Zhang, Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007; 62: 970–976.CrossRefGoogle ScholarPubMed

  3. Ermer, J, Homolka, R, Martin, P, Buckwalter, M, Purkayastha, J, Roesch, BG. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers. Poster presented at: U.S. Psychiatric and Mental Health Congress, October 30-November 2, 2008; San Diego, CA.Google Scholar

  4. Biederman, J, Krishnan, S, Zhang, Y, McGough, JJ, Findling, RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007; 29: 450–463.CrossRefGoogle ScholarPubMed

  5. Wigal, SB, Kollins, SH, Squires, LA, Childress, AC. Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.Google Scholar

  6. Findling, R, Jain, R, Gao, J, Richards, C, Ginsberg, L. A dose-optimization study of the efficacy, safety, and tolerability of lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.Google Scholar

  7. Schachter, HM, Pham, B, King, J, Langford, S, Moher, D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001; 165: 1475–1488.Google ScholarPubMed

  8. Faraone, SV, Biederman, J, Roe, C. Comparative efficacy of Adderall and methlphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002; 22: 468–473.CrossRefGoogle Scholar

  9. Biederman, J, Faraone, SV, Monuteaux, MC, Grossbard, JR. How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatements? A pooled analysis of parents' and teachers' reports. Pediatrics. 2004; 113: 1667–1671.CrossRefGoogle Scholar

  10. Biederman, J, Gao, H, Rogers, AK, Spencer, TJ. Comparison of parent and teacher reports of attentions-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006; 60: 1106–1110.CrossRefGoogle ScholarPubMed

  11. Sallee, FR, Ambrosini, PJ, López, FA, Shi, L, Michaels, MA; LADD.CAT Study Group. Health-related quality of life and treatment satisfaction and preference in a community assessment study of extended-release mixed amphetamine salts for children with attention-deficit/hyperactivity disorder J Outcomes Res. 2004; 8: 27–49.Google Scholar

  12. Trattler, W, Katsev, D, Kerney, D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Clin Ther. 2006; 28: 1848–1856.CrossRefGoogle ScholarPubMed

  13. Kerney, DL, Paradis, D, Brunton, S. Patient perceptions of insulin detemir as reported through patient telephone surveys. Curr Med Res Opin. 2007; 23: 2043–2049.CrossRefGoogle ScholarPubMed